Nuri Tutar

Nuri Tutar

Auto-generated profile, based on publicly available information

Nuri Tutar

Erciyes Universitesi

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2013 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
NTNuri Tutar
Nuri Tutar
GMGökhan Metan
Gökhan Metan
AKAyşe Nedret Koç
Ayşe Nedret Koç
IYInsu Yilmaz
Insu Yilmaz
IBIlkay Bozkurt
Ilkay Bozkurt
RDRamazan Demir
Ramazan Demir
Invasive pulmonary aspergillosis (IPA) is an infection often occurring in neutropenic patients and has high mortality rates. In recent years, it has been reported that the incidence of IPA has also increased in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the clinical and demographic characteristics and treatment responses of IPA in patients with COPD.

6 April 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
IYİnsu Yilmaz
İnsu Yilmaz
MTMurat Türk
Murat Türk
SBSakine Bahçeci̇oğlu
Sakine Bahçeci̇oğlu
NTNuri Tutar
Nuri Tutar
IGİnci Gülmez
İnci Gülmez
Oral corticosteroid (OCS)-dependent severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps (SEA-CRSwNP) would be a suitable phenotype for mepolizumab treatment. This study evaluated the short-term efficacy of mepolizumab treatment in OCS-dependent SEA-CRSwNP. Baseline and 24th week results [daily OCS doses, asthma exacerbation frequency, asthma control test (ACT) scores, blood eosinophil levels, FEV1 values, and numerical analog scale (NAS) of CRSwNP symptoms] of patients who were treated for at least 24 weeks with mepolizumab were retrospectively evaluated and compared. A total of 16 patients were enrolled in the study. Mepolizumab was discontinued in one patient due to side effects. The daily OCS dosage was reduced from baseline in all patients, and at week 24 OCS was discontinued in 40% of the patients (baseline mean steroid dose: 9.2 ± 5.2 mg, 24th week: 1.3 ± 1.4 mg; P < 0.001). The number of asthma exacerbations within 24 weeks significantly decreased after beginning mepolizumab treatment (2.1 ± 2.7 vs. 0.07 ± 0.26; P = 0.012), and a significant increase in ACT scores (baseline mean ACT: 18 ± 5.7; 24th week mean ACT: 23.3 ± 3; P = 0.006) was observed despite the decrease in daily OCS dosages. There was no significant difference in FEV1 values between baseline and week 24. Evaluation of the general symptoms of CRSwNP, as per NAS, revealed that the baseline mean NAS was 5.6 ± 4.4, and the 24th week mean NAS was 3.2 ± 3.2 (P = 0.021). This is the first real-life study evaluating the short-term efficacy of mepolizumab treatment on OCS-dependent SEA-CRSwNP. This study demonstrates that mepolizumab is an effective and safe biologic for the treatment of this severe asthma subphenotype.

13 August 2025 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
BBBurcu Baran
Burcu Baran
NYNur Aleyna Yetkin
Nur Aleyna Yetkin
BRBilal Rabahoğlu
Bilal Rabahoğlu
NTNuri Tutar
Nuri Tutar
IGİnCi Gülmez
İnCi Gülmez
Background: Pneumonia is a lung parenchyma infection with clinical presentations ranging from mild to life‐threatening. Its severity depends on factors such as the causative pathogen, the host's immune response, and existing comorbidities. This study aimed to investigate the prognostic value of novel inflammatory biomarkers for predicting in‐hospital mortality in patients with community‐acquired pneumonia (CAP).Methods: This retrospective cross‐sectional study included 207 hospitalized patients diagnosed with clinically and radiologically confirmed pneumonia. Laboratory data collected upon admission included complete blood count parameters, C‐reactive protein (CRP), creatinine, and albumin levels. Systemic inflammatory biomarkers such as the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), CRP‐to‐albumin ratio (CAR), CRP‐to‐lymphocyte ratio (CLR), systemic immune‐inflammation index (SII), systemic inflammatory response index (SIRI), prognostic nutritional index (PNI), and C‐reactive protein‐albumin‐lymphocyte (CALLY) index were calculated.Results: The cohort was predominantly male (69%, n = 142) with a mean age of 62.1 ± 16.3 years. The median hospital stay was 8 days, with an 11% mortality rate. Malignancy was more frequent in the nonsurvivor group (p = 0.001). Nonsurvivors had significantly lower hemoglobin (p < 0.001) and albumin (p = 0.004) levels, while CRP (p = 0.024) and creatinine (p = 0.002) were elevated. NLR (p = 0.009), CAR (p = 0.011), CLR (p = 0.006), SII (p = 0.013), and SIRI (p = 0.024) were higher in nonsurvivors, while PNI (p = 0.010) and CALLY (p = 0.003) were lower.Conclusion: Novel inflammatory biomarkers, particularly the CALLY index, are valuable for mortality prediction in CAP, aiding in risk stratification and early management.

1 January 2017 in Endoscopic Ultrasound
Verified
Journal Article
Open access
PDF file
NTNuri Tutar
Nuri Tutar
ECErdoğan Cetinkaya
Erdoğan Cetinkaya
OUOzan Usluer
Ozan Usluer
AYAydın Yılmaz
Aydın Yılmaz
EÇErtan Çam
Ertan Çam
NDNilgün Yılmaz Demirci
Nilgün Yılmaz Demirci
Background and Objectives: Selecting the diagnostic procedure for mediastinal restaging after chemotherapy and/or radiotherapy in Stage IIIA-N2 non-small cell lung cancer (NSCLC) patients remains a problem. The aim of the study was to determine the efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the evaluation of mediastinal lymph nodes in the restaging of NSCLC patients. Materials and Methods: The present multicentric study retrospectively analyzed the results of Stage IIIA-N2 NSCLC patients who had undergone EBUS for mediastinal restaging after preoperative chemotherapy or radiotherapy or both. Results: In 44 patients with 73 N2 nodes, malignant cells were identified in EBUS-TBNA from 23 patients (57.5%) and 25 lymph nodes (34.2%). Twenty-one patients (42.5%) and 48 lymph nodes (65.8%) were negative for nodal metastasis. All of these patients with negative results subsequently underwent mediastinoscopy or surgery (n = 9 and n = 12, respectively). Metastasis was detected in 5 (23.8%) of 21 patients and 6 (12.5%) of 48 lymph nodes. The diagnostic sensitivity, specificity, positive predictive value, negative predicted value and accuracy of EBUS-TBNA based on number of patients were 82.1%, 100%, 100%, 76.2%, and 88.6%, respectively. Conclusions: EBUS-TBNA should be done before invasive procedures in restaging of the mediastinum in patients previously treated with neoadjuvant therapy because of high diagnostic accuracy rate. However, negative results should be confirmed with invasive procedures such as mediastinoscopy and thoracoscopy.

22 September 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
KGKursat Gundogan
Kursat Gundogan
İAİsmail Hakkı Akbudak
İsmail Hakkı Akbudak
PHPervin Hancı
Pervin Hancı
BHBurcin Halaci
Burcin Halaci
STSahin Temel
Sahin Temel
ATArzu Topeli
Arzu Topeli
There are limited data on the long-term outcomes of COVID-19 from different parts of the world. To determine risk factors of 90-day mortality in critically ill patients in Turkish intensive care units (ICUs), with respiratory failure. Retrospective, observational cohort. Patients with laboratory-confirmed COVID-19 and who had been followed up in the ICUs with respiratory failure for more than 24 hours were included in the study. Their demographics, clinical characteristics, laboratory variables, treatment protocols, and survival data were recorded. A total of 421 patients were included. The median age was 67 (IQR: 57-76) years, and 251 patients (59.6%) were men. The 90-day mortality rate was 55.1%. The factors independently associated with 90-day mortality were invasive mechanical ventilation (IMV) (HR 4.09 [95% CI: [2.20-7.63], P < .001), lactate level >2 mmol/L (2.78 [1.93-4.01], P < .001), age ≥60 years (2.45 [1.48-4.06)], P < .001), cardiac arrhythmia during ICU stay (2.01 [1.27-3.20], P = .003), vasopressor treatment (1.94 [1.32-2.84], P = .001), positive fluid balance of ≥600 mL/day (1.68 [1.21-2.34], P = .002), PaO2/FiO2 ratio of ≤150 mmHg (1.66 [1.18-2.32], P = .003), and ECOG score ≥1 (1.42 [1.00-2.02], P = .050). Long-term mortality was high in critically ill patients with COVID-19 hospitalized in intensive care units in Turkey. Invasive mechanical ventilation, lactate level, age, cardiac arrhythmia, vasopressor therapy, positive fluid balance, severe hypoxemia and ECOG score were the independent risk factors for 90-day mortality.

1 January 2014 in Annals of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
EÇErdogan Çetinkaya
Erdogan Çetinkaya
MÖM. Akif Özgül
M. Akif Özgül
NTNuri Tutar
Nuri Tutar
GÖGüler Özgül
Güler Özgül
EÇErtan Çam
Ertan Çam
SBSemra Bilaçeroǧlu
Semra Bilaçeroǧlu
Background: There are many causes of mediastinal and hilar lymphadenopathy, such as neoplasms, granulomatous diseases, infections and reactive hyperplasia. Nowadays, the popularity of endobronchial ultrasound-guided transbronchial needle aspiration (EBUSTBNA) is increasing in the diagnosis of mediastinal and hilar lymphadenopathy. We aimed to investigate the diagnostic value of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathy and previously conventional TBNA-negative or inadequate results. Methods: Retrospective analysis was performed in 64 patients with previously conventional TBNA- negative or inadequate results and consequently undergoing EBUS-TBNA between July 2007 and August 2011. Results: One hundred and twenty three lymph nodes were sampled by EBUS-TBNA in 64 patients with no complications. In the 63 (98.4%) cases with adequate results, the sensitivity, diagnostic accuracy, and NPV of EBUS-TBNA per patient was 90.5%, 90.6%, and 66.6%, respectively. In a total of 122 (99.1%) adequately sampled lymph nodes, the diagnostic sensitivity, accuracy, and NPV of EBUS-TBNA per nodal station were 87.8%, 90.1%, and 65.7%, respectively. Non-small cell lung cancer (NSCLC) (n = 21, 33.3%) and sarcoidosis (n = 16, 25.3%) were the most common malignant and benign diseases in the patients with adequate samples by EBUS-TBNA. The relationships of diagnostic accuracy with the number of lymph nodes sampled, number of passes per node, or size of lymph nodes were both insignifi cant (p >0.05). Conclusion: EBUS-TBNA is a sensitive and accurate method for the assessment of mediastinal and hilar lymph nodes in patients with conventional TBNA negative results.